Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
HK$ 32.7
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of endocrine therapies in the People's Republic of China, Hong Kong, and Taiwan. Its lead product, Lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. The company also develops TransCon CNP (navepegritide), a long-acting prodrug...
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA, overpriced on P/FC
Data is available to registered users only
Buy
Sell